Replies to post #221802 on Cytodyn Inc (CYDY)

[misiu143]

Yes , I will expect Amarex will need to pay a lot ..

We finished combo study , pivotal phase 3 in February of 2018 .

At this time only 2 drugs were approved for MDR patients ..( multi drug resistance )

And one of them ibalizumab approved only for MDR 3 patients with IV infusion every 2 weeks and efficacy of 43% .

Another Maraviroc also approved for MDR 2 , with 45% efficacy and Black Box warning for severe side effects .

Leronlimab would be approve for MDR 2 and MDR 3 and efficacy was 81% , and not one serious side effect ..,
so treating only conservatively about 10% of proper patients , R 5 HIV strain , only 10% …
charging 70,000 a year , Ibalizumab charging 125,000 a year .
Cydy will make ONLY in USA 1.25 B doll a year , only in USA , how about internationally ..

So when they saying “ exceeding 100M “ it should be exceeding a lot .,

All imo .

GLTA longs .